株式会社フェニックスバイオ

HBVZ10, an AAV8 vector-based new HBV therapy candidate for cccDNA elimination

Zhang, B. H. Zhou, Y. Horrigan, S. Luckenbaugh, L. Hu, J. Zoulim, F. Zhang, Y. Y.
Mol Ther Methods Clin Dev. 2025 Nov 19;33(4):101646. doi: 10.1016/j.omtm.2025.101646.

READ MORE(PUB MED)

Netrin-1 inhibits the attachment and internalization of Hepatitis B virus for hepatocyte infection

Wang, Y. Murai, K. Ishida, A. Kawasaki, N. Kuroki, K. Li, Y. Y. Sato, Y. Miura, Y. Takara, K. Kong, L. Shimakami, T. Nio, K. Higuchi, Y.Suemizu, H. Ito, S. Yanagawa, H. Kaneko, S. Yamashita, T. Honda, M.
PLoS Pathog. 2025 Dec 17;21(12):e1013776. doi: 10.1371/journal.ppat.1013776.

READ MORE(PUB MED)

Replication-driven HBV cccDNA loss in chimeric mice with humanized livers

Zhang, B. H. Zhou, Y. Horrigan, S. Zoulim, F. Hu, J. Zhang, Y. Y.
J Virol. 2025 Nov 6:e0129525. doi: 10.1128/jvi.01295-25.

READ MORE(PUB MED)

RXR agonist S169 inhibits HBV/HDV entry in vitro by disrupting KIF4-dependent NTCP trafficking

Gad, S. A. Abo Elwafa, D. A. Hussein, S. A. Fukano, K. Kato, T. Shoji, I. Chayama, K. Muramatsu, M. Isogawa, M. Wakita, T. Merk, D. Aly, H. H.
Antiviral Res. 2025 Aug;240:106214. doi: 10.1016/j.antiviral.2025.106214.

READ MORE(PUB MED)

A novel synthetic bile acid derivative inhibits hepatitis B virus infection at entry step by interfering with the oligomerization of sodium taurocholate co-transporting polypeptide

Rsi Suwardana, G. N. Abe, T. Deng, L. Matsui, C. Okitsu, T. Yamada, T. Hatano, M. Wiriyasermkul, P. Nagamori, S. Gad, S. A. Aly, H. H. Nishitsuji, H. Shimotohno, K. Shoji, I.
Antiviral Res. 2025 Aug 30;243:106267. doi: 10.1016/j.antiviral.2025.106267.

READ MORE(PUB MED)

Potential for Core Fucose-Targeted Therapy Against HBV Infection of Human Normal Hepatocytes

Takamatsu, S. Morita, C. Sakon, D. Nakamura, K. Hishii, H. Kondo, J. Ueda, K. Miyoshi, E.
Viruses. 2025 Sep 15;17(9):1242. doi: 10.3390/v17091242.

READ MORE(PUB MED)

Modeling of hepatitis B virus infection spread in primary human hepatocytes

Shi, Z. Tsuge, M. Collier, N. Takeuchi, Y. Uchida, T. Rutter, C. M. Teraoka, Y. Uprichard, S. L. Ishida, Y. Tateno, C. Ozik, J. Dahari, H. Chayama, K.
J Virol. 2025 Aug 4:e0092725. doi: 10.1128/jvi.00927-25.

READ MORE(PUB MED)

Assessing hepatitis B virus infectivity in blood components following pathogen reduction using a human hepatocyte model

Visser, B. J. Biswas, S. Eltahan, R. Fares-Gusmao, R. Yegneswaran, S. Mufti, N. Villa, C. H. McGivern, D. R.
Transfusion. 2025 Jul 24. doi: 10.1111/trf.18357.

READ MORE(PUB MED)

miRNA-29b-1-5p mediates an antiviral activity by targeting the HBV entry receptor in human hepatocytes

Gailhouste, L. Furutani, Y. Qin, X. Y. Higuchi, S. Toguchi, M. Yanaka, K. Watashi, K. Wakita, T. Kojima, S.
Sci Rep. 2025 Jul 3;15(1):23725. doi: 10.1038/s41598-025-09655-y.

READ MORE(PUB MED)

Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection

Zhou, J. Kaiser, H. Rocha, E. Terrell, A. N. Corti, D. Purcell, L. A. Lempp, F. A. Puschnik, A. S.
JHEP Rep. 2025 Mar 22;7(6):101400. doi: 10.1016/j.jhepr.2025.101400. eCollection

READ MORE(PUB MED)

Clinical potential of SAG-524: A novel HBV RNA destabilizer with a unique mechanism of action

Tanaka, Yasuhito
Glob Health Med. 2025 Feb 28;7(1):64-66. doi: 10.35772/ghm.2024.01078.

READ MORE(PUB MED)

Identification of glycogen synthase kinase 3alpha/beta as a host factor required for HBV transcription using high-throughput screening

Nishitsuji, H. Naito, Y. Murakami, Y. Sugiyama, M. Mizokami, M. Shoji, I. Murata, T. Shimotohno, K.
Hepatology. 2025 Jan 23. doi: 10.1097/HEP.0000000000001239.

READ MORE(PUB MED)

Identification of novel antiviral host factors by functional gene expression analysis using in vitro HBV infection assay systems

Nosaka, T. Naito, T. Akazawa, Y. Takahashi, K. Matsuda, H. Ohtani, M. Nishizawa, T. Okamoto, H. Nakamoto, Y.
PLoS One. 2025 Mar 6;20(3):e0314581. doi: 10.1371/journal.pone.0314581.

READ MORE(PUB MED)

Endothelial lipase-binding peptides similar to netrin-1 inhibit hepatitis B virus infection

Ide, M. Tabata, N. Murai, K. Yonemura, Y. Wang, Y. Ishida, A. Shirasaki, T. Kaneko, S. Ito, S. Honda, M. Yanagawa, H.
FEBS Lett. 2025 Jan 25. doi: 10.1002/1873-3468.15101.

READ MORE(PUB MED)

Hepatitis B virus genotypes A1 and A2 have distinct replication phenotypes due to polymorphisms in the HBx gene

Zhang, M. Mouzannar, K. Zhang, Z. Teraoka, Y. Piotrowski, J. Ishida, Y. Tateno-Mukaidani, C. Saito, T.Abe-Chayama, H. Chayama, K.Liang, T. J.
PLoS Pathog. 2025 Jan 9;21(1):e1012803. doi: 10.1371/journal.ppat.1012803.

READ MORE(PUB MED)

Alteration of Gene Expression After Entecavir and Pegylated Interferon Therapy in HBV-Infected Chimeric Mouse Liver

Bao, H. Murakami, S. Tsuge, M. Uchida, T. Uchikawa, S. Fujino, H. Ono, A. Murakami, E. Kawaoka, T. Miki, D. Hayes, C. N. Oka, S.
Viruses. 2024 Nov 6;16(11):1743. doi: 10.3390/v16111743.

READ MORE(PUB MED)

Modelling of hepatitis B virus kinetics and accumulation of cccDNA in primary human hepatocytes

Louis Shekhtman, Yuji Ishida, Masataka Tsuge, Vladimir Reinharz, Mikaru Yamao, Masaki Takahashi, Chise Tateno, Susan L. Uprichard, Harel Dahari, Kazuaki Chayama
JHEP Reports https://doi.org/10.1016/j.jhepr.2024.101311.

READ MORE(PUB MED)

Infectivity of Hepatitis B Virus Surface Antigen-Positive Plasma With Undetectable HBV-DNA: Can HBsAg Screening Be Discontinued in Egyptian Blood Donors?

El Ekiaby, M. Tanaka, J. van Drimmelen, H. Allain, J. P. Lelie, N.
J Viral Hepat. 2024 Aug 10. doi: 10.1111/jvh.13990.

READ MORE(PUB MED)

Interferon alpha induces a stronger antiviral effect than interferon lambda in HBV/HDV infected humanized mice

Duehren, S. Uchida, T. Tsuge, M. Hiraga, N. Uprichard, S. L. Etzion, O. Glenn, J. Koh, C. Heller, T. Cotler, S. J. Oka, S. Chayama, K. Dahari, H.
Virus Res. 2024 Aug 26;349:199451. doi: 10.1016/j.virusres.2024.199451.

READ MORE(PUB MED)

Lipid nanoparticle-encapsulated DOCK11-siRNA efficiently reduces hepatitis B virus cccDNA level in infected mice

Okada, H. Sakamoto, T. Nio, K. Li, Y. Kuroki, K. Sugimoto, S. Shimakami, T. Doi, N. Honda, M. Seiki, M. Kaneko, S. Yamashita, T.
Mol Ther Methods Clin Dev. 2024 Jun 24;32(3):101289. doi: 10.1016/j.omtm.2024.101289.

READ MORE(PUB MED)

研究発表

HBVZ10, an AAV8 vector-based new HBV therapy candidate for cccDNA elimination

Netrin-1 inhibits the attachment and internalization of Hepatitis B virus for hepatocyte infection

Replication-driven HBV cccDNA loss in chimeric mice with humanized livers

RXR agonist S169 inhibits HBV/HDV entry in vitro by disrupting KIF4-dependent NTCP trafficking

A novel synthetic bile acid derivative inhibits hepatitis B virus infection at entry step by interfering with the oligomerization of sodium taurocholate co-transporting polypeptide

Potential for Core Fucose-Targeted Therapy Against HBV Infection of Human Normal Hepatocytes

Modeling of hepatitis B virus infection spread in primary human hepatocytes

Assessing hepatitis B virus infectivity in blood components following pathogen reduction using a human hepatocyte model

miRNA-29b-1-5p mediates an antiviral activity by targeting the HBV entry receptor in human hepatocytes

Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection

Clinical potential of SAG-524: A novel HBV RNA destabilizer with a unique mechanism of action

Identification of glycogen synthase kinase 3alpha/beta as a host factor required for HBV transcription using high-throughput screening

Identification of novel antiviral host factors by functional gene expression analysis using in vitro HBV infection assay systems

Endothelial lipase-binding peptides similar to netrin-1 inhibit hepatitis B virus infection

Hepatitis B virus genotypes A1 and A2 have distinct replication phenotypes due to polymorphisms in the HBx gene

Alteration of Gene Expression After Entecavir and Pegylated Interferon Therapy in HBV-Infected Chimeric Mouse Liver

Modelling of hepatitis B virus kinetics and accumulation of cccDNA in primary human hepatocytes

Infectivity of Hepatitis B Virus Surface Antigen-Positive Plasma With Undetectable HBV-DNA: Can HBsAg Screening Be Discontinued in Egyptian Blood Donors?

Interferon alpha induces a stronger antiviral effect than interferon lambda in HBV/HDV infected humanized mice

Lipid nanoparticle-encapsulated DOCK11-siRNA efficiently reduces hepatitis B virus cccDNA level in infected mice